A novel physiologically-based pharmacokinetic model to estimate reduced CYP3A4 activity in cancer patients utilizing the neutrophil-to-lymphocyte ratio as an inflammatory marker.
Saved in:
| Title: | A novel physiologically-based pharmacokinetic model to estimate reduced CYP3A4 activity in cancer patients utilizing the neutrophil-to-lymphocyte ratio as an inflammatory marker. |
|---|---|
| Authors: | Coutant DE; Drug Disposition Department, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, DC0720 46285, USA. cout@lilly.com., Rehmel J; Global PK/PD and Pharmacometrics, Eli Lilly and Company, Indianapolis, Indiana, USA., Edwards DM; Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA., Hall SD; Drug Disposition Department, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, DC0720 46285, USA. |
| Source: | European journal of clinical pharmacology [Eur J Clin Pharmacol] 2025 Jun; Vol. 81 (6), pp. 853-862. Date of Electronic Publication: 2025 Apr 05. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Country of Publication: Germany NLM ID: 1256165 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1041 (Electronic) Linking ISSN: 00316970 NLM ISO Abbreviation: Eur J Clin Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-1041 |
|---|---|
| DOI: | 10.1007/s00228-025-03839-1 |
